Compare GE Vernova Inc (GEV) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Invesco Ltd. — how do they compare? GE Vernova Inc trades at $1,005.78 (market cap $266.16B), while Invesco Ltd. trades at $29.56 (market cap $13.28B). The key difference: GE Vernova Inc is far larger — about 20× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Invesco Ltd. for 77 Days on average.
| GEV | IVZ | |
|---|---|---|
Market Cap | $266.16B | $13.28B |
Volume | 2,324,165 | 3,698,033 |
Sector | Industrials | Financials |
52-Week High | $1.17K | $33.31 |
52-Week Low | $547.96 | $22.44 |
Typical Hold Time | 36 Days | 77 Days |
Enterprise Value | $255.83B | $23.45B |
Dividend Yield | 0.2% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $986.62, down 1.05% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical momentum with support at $973 and resistance at $1,026. Recent Q1 2026 earnings beat expectations with EPS of $17.44 versus $1.95 expected, while Q2 2026 missed estimates. The company secured the first US construction permit for its BWRX-300 small modular reactor, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with projected revenue growth to $41.4B in 2026 and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and EV/EBITDA of 85.22, plus execution challenges in scaling nuclear projects. The stock offers exposure to AI infrastructure growth but requires monitoring of margin expansion and backlog conversion.
Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.
The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
